Result of AGM

RNS Number : 9470M
Advanced Medical Solutions Grp PLC
02 June 2010

For immediate release: 2 June 2010


Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)


Result of Annual General Meeting


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, held its Annual General Meeting today, at which all resolutions put to shareholders were duly passed.


Dr. Don Evans, AMS’s Chief Executive, gave a presentation at the AGM, the slides from which will be made available on the Company’s website


ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Don Evans, Chief Executive Officer                                                              Tel: +44 (0) 1606 545508

Mary Tavener, Finance Director

Chris Meredith, Chief Operating Officer


Tavistock Communications

John West / Chris Munden                                                                         Tel: +44 (0) 20 7920 3150


Investec Bank plc

Gary Clarence / Daniel Adams                                                                    Tel: +44 (0) 20 7597 5970


Notes to Editors:


AMS advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foam. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. The inclusion of silver adds a proven effectiveness against antibiotic resistant bacteria.


AMS wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). The business is debt free, profitable, cash generative and the Board recently announced that its intention is to recommend a maiden dividend for the year ended 31st December 2010.


In 2009, AMS delivered a 19% increase in revenues, a 51% increase in operating profit before exceptionals, and a strong, debt-free, year-end balance sheet. The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities.

This information is provided by RNS
The company news service from the London Stock Exchange